Recursion Pharmaceuticals RXRX
Recursion Pharmaceuticals, Inc. · Nasdaq · Biological Products, (No Diagnostic Substances)
$4.35+7.41%close on Oct. 28, 2026 · volume 28.4M · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 6, 2026 | Blake Borgeson director | Sold 10b5-1 plan | 50,000 | $4.84 | $242,000 |
| Oct. 6, 2026 | Robert Hershberg director | Sold 10b5-1 plan | 25,000 | $5.00 | $125,000 |
| Sept. 8, 2026 | Najat Khan CEO and President, director | Sold 10b5-1 plan | 22,408 | $3.52 | $78,822 |
| Sept. 1, 2026 | Blake Borgeson director | Sold 10b5-1 plan | 30,000 | $3.34 | $100,200 |
| Aug. 4, 2026 | Blake Borgeson director | Sold 10b5-1 plan | 30,000 | $3.25 | $97,500 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 21 →Entry into a material definitive agreement · Results of operations and financial condition · Regulation FD disclosure · Other events · Financial statements and exhibits
Entry into a material definitive agreement